Cingulate Inc.

Equities

CING

US17248W2044

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 01:30:00 29/06/2024 am IST			5-day change	1st Jan Change
0.32 ^USD	-45.21%		-44.79%	-95.82%

21/05	FDA Clears Cingulate to File for Marketing Approval of CTx-1301 in the Treatment of ADHD	CI
08/05	Cingulate Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Scott Applebaum Provides Cingulate Inc. with Notice of His Resignation from the Board of Directors

December 13, 2023 at 03:30 am IST

On December 6, 2023, Scott Applebaum provided Cingulate Inc. with notice of his resignation from the Board of Directors. Mr. Applebaum?s decision to resign was not the result of any disagreement with the Company or its management on any matter relating to the Company?s operations, policies or practices.

Latest news about Cingulate Inc.

FDA Clears Cingulate to File for Marketing Approval of CTx-1301 in the Treatment of ADHD	21/05	CI
Cingulate Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	08/05	CI
Certain Pre-Funded Warrants of Cingulate Inc. are subject to a Lock-Up Agreement Ending on 7-MAY-2024.	07/05	CI
Certain Warrants of Cingulate Inc. are subject to a Lock-Up Agreement Ending on 7-MAY-2024.	07/05	CI
Certain Stock Options of Cingulate Inc. are subject to a Lock-Up Agreement Ending on 7-MAY-2024.	07/05	CI
Certain Common Stock of Cingulate Inc. are subject to a Lock-Up Agreement Ending on 7-MAY-2024.	07/05	CI
Cingulate Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	01/04	CI
Cingulate Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	01/04	CI
Cingulate Appoints Jay Roberts, Bryan Lawrence, and Jeff Ervin to Its Board of Directors	13/02	CI
Top Midday Decliners	03/02	MT
Global markets live: Meta, Amazon, Apple, Tesla, Intel...	02/02
Cingulate Prices $7.5 Million Public Offering; Shares Plunge	02/02	MT
Cingulate Inc. Appoints Jennifer L. Callahan as Senior Vice President	29/01	CI
Cingulate Inc. Announces Promotion of Jennifer Callahan as Chief Financial Officer	29/01	CI
HC Wainwright Adjusts Price Target on Cingulate to $8 From $3.50, Maintains Buy Rating	05/01	MT
Wall Street Set for Cautious Opening in Final Trading Day of a Bullish 2023	29/12	MT
Index Futures Edge Higher to End Mostly Positive Year on High Note	29/12	MT
Top Premarket Decliners	29/12	MT
Wall Street Futures Gain in Early Action Ahead of Last Trading Day of 2023	29/12	MT
Top Premarket Gainers	28/12	MT
Wall Street Futures Lean Lower Premarket Thursday; Volumes Remain Thin Towards Year-End	28/12	MT
Top Premarket Gainers	27/12	MT
Laidlaw Downgrades Cingulate to Hold From Buy	22/12	MT
North American Morning Briefing : S&P 500 Futures -2-	20/12	DJ
North American Morning Briefing : S&P 500 Eyes -2-	19/12	DJ

Chart Cingulate Inc.

Duration

Period

More charts

Company Profile

Cingulate Inc. is a biopharmaceutical company. The Company is focused on the development, manufacturing, and commercialization of pharmaceutical products that utilize its precision timed release (PTR) drug delivery platform technology to create dosing schedules and drug release profiles. It focuses on the treatment of attention deficit/hyperactivity disorder (ADHD). The Company is in the development of two lead product candidates, such as CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine). The Companyâs CTx-1301 and CTx-1302 are being developed for the treatment of ADHD in the three core patient segments: children (ages 6-12), adolescents (ages 13-17), and adults (ages18+). In addition, the Company has a third product to treat anxiety, CTx-2103, in a formulation stage. Its CTx-1301, CTx-1302 and CTx-2103 drug candidates contain three releases of active pharmaceutical ingredient combined into one small tablet dosage form.

Sector

Biotechnology & Medical Research

Calendar

12/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

0.32 USD

Average target price

14 USD

Spread / Average Target

+4,275.00%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
CINGULATE INC.	-95.82%	2.21M
MODERNA, INC.	+19.41%	45.51B
LONZA GROUP AG	+38.65%	39.36B
IQVIA HOLDINGS INC.	-8.62%	38.52B
ALNYLAM PHARMACEUTICALS, INC.	+26.95%	30.74B
CELLTRION, INC.	-13.50%	26.03B
ICON PUBLIC LIMITED COMPANY	+10.74%	25.92B
UNITED THERAPEUTICS CORPORATION	+44.87%	14.13B
MEDPACE HOLDINGS, INC.	+34.36%	12.73B
BIO-TECHNE CORPORATION	-7.14%	11.29B

Other Biotechnology & Medical Research